Clin2
NCT05505812Possibly a fitNot yet recruiting

Autologous immune cell treatment for advanced breast cancer safety

Breast Cancer

Treatments studied

Part of Cancer, Skin clinical trials.

This trial tests a lab-made immune therapy made from your own tumor cells, to treat advanced breast cancer that has not responded to first treatments. The main goal is to check safety and see whether it can help control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
10 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are a woman age 18 to 75 and have advanced breast cancer confirmed by lab testing (tissue or cell samples).
  • Your breast cancer has already tried first-line standard treatment and either did not work or there are no effective options left (or you do not want more standard treatment).
  • You have at least one tumor spot that can be removed and has not had radiation or other local treatment in the last 28 days, or a tumor spot that can provide enough immune cells for the lab process.
  • You have at least one measurable tumor spot on scans that is considered measurable by RECIST rules, and it has not had local treatment in the last 28 days (unless it clearly grew after those treatments).
  • You are generally well enough for study treatment: performance status (ECOG) 0–2, expected life span over 3 months, and blood tests/organ function (liver, kidneys, blood clotting) meet minimum thresholds.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05142475Recruiting· Early Phase 1
Study of GC101 tumor-infiltrating cells for advanced breast cancer

This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.

Shanghai
NCT06532812Recruiting· Phase 1/Phase 2
TIL therapy plus immunotherapy for advanced breast cancer

This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.

Beijing, Beijing Municipality
NCT04430595Not yet recruiting· Phase 1/Phase 2
Modified immune cells for advanced breast cancer

This trial tests a new therapy where your immune cells are modified to better recognize and attack breast cancer cells. It is for people with advanced or recurrent breast cancer that has certain markers on the tumor cells.

Shenzhen, Guangdong
NCT04842812Recruiting· Phase 1
Personalized immune cell therapy for advanced solid tumors

This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.

Guangzhou
NCT05539768Not yet recruiting· Early Phase 1
Trial uses your tumor’s immune cells for advanced solid cancers

This early-phase trial tests whether collecting immune cells from your tumor (tumor infiltrating lymphocytes) is safe and can help treat advanced solid cancers. It may help by strengthening your body’s immune attack on the cancer after standard treatments are no longer working.

NCT06342336Recruiting· Phase 1
HS-IT101 injection for advanced solid tumors

This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.

Beijing, Beijing Municipality

Hear when a new Breast cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.